Kojin Pharmaceutical-B (02171): CT1190B has received IND approval from the National Medical Products Administration for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least second-line standard treatment.

Zhitong Finance APP news, Keji Pharmaceuticals-B (02171) announced that CT1190B, a universal CAR-T cell product targeting CD19/CD20, has obtained IND approval from the National Medical Products Administration for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least second-line standard therapy. The results of the IIT study of CT1190B have been presented in a poster at the 2026 European Hematology Association Annual Meeting.